Nectin-4 (Nectin cell adhesion molecule 4), a type I transmembrane cell adhesion protein,
was demonstrated to be overexpressed in a variety of tumors, making it an attractive antigen …

Simple Summary A rapidly emerging new approach to treat cancer involves collection of
patient immune white blood cells and genetic re-programming of the cells to express a new …

Background Triple-negative breast cancer (TNBC) is more prone to distant metastasis and
visceral recurrence in comparison to other breast cancer subtypes, and is related to dismal …

Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system.
Although there are various treatment modalities, including surgery, chemotherapy, and …

Angiogenesis, barriergenesis, and immune cell migration are all key physiological events
that are dependent on the functional characteristics of the vascular endothelium. The protein …

PURPOSE Aberrant expression of nectin-4 (N4) has been observed in several malignancies
emerging as new target for antibody-drug conjugates, especially in urothelial carcinoma of …

Antibody‐drug conjugates (ADCs) represent a novel type of targeted cancer therapy
combining the specificity of monoclonal antibodies with the cytotoxicity of conventional …

Antibody–drug conjugates (ADCs) consist of monoclonal antibodies that target tumor cells
and cytotoxic drugs linked through linkers. By leveraging antibodies' targeting properties …

Radiopharmaceuticals play a critical role in nuclear medicine, providing novel tools for
specifically delivering radioisotopes for the diagnosis and treatment of cancers. As the …

In the ever-evolving landscape of cancer research, immuno-oncology stands as a beacon of
hope, offering novel avenues for treatment. This study capitalizes on the vast repository of …